LivaNova (LIVN)
Market Price (5/24/2026): $73.76 | Market Cap: $4.0 BilSector: Health Care | Industry: Health Care Equipment
LivaNova (LIVN)
Market Price (5/24/2026): $73.76Market Cap: $4.0 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% Low stock price volatilityVol 12M is 38% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Chronic Disease Management, and Targeted Therapies. | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% Weak multi-year price returns2Y Excs Rtn is -22%, 3Y Excs Rtn is -19% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 25x, P/EPrice/Earnings or Price/(Net Income) is 38x Key risksLIVN key risks include [1] a slow growth rate in its neuromodulation segment and [2] a significant $363 million liability ruling in Italy and ongoing SNIA litigation. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Low stock price volatilityVol 12M is 38% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Chronic Disease Management, and Targeted Therapies. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% |
| Weak multi-year price returns2Y Excs Rtn is -22%, 3Y Excs Rtn is -19% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 25x, P/EPrice/Earnings or Price/(Net Income) is 38x |
| Key risksLIVN key risks include [1] a slow growth rate in its neuromodulation segment and [2] a significant $363 million liability ruling in Italy and ongoing SNIA litigation. |
Qualitative Assessment
AI Analysis | Feedback
1. Strong First-Quarter 2026 Financial Performance and Raised Full-Year Guidance.
LivaNova reported adjusted diluted earnings per share (EPS) of $0.98 for Q1 2026, significantly surpassing analyst estimates of $0.91 to $0.85. Additionally, the company's revenue reached $362.3 million, exceeding expectations of $353.03 million to $346.05 million. This strong performance, marked by 14.3% reported revenue growth and 11.1% constant-currency growth year-over-year, led LivaNova to raise its full-year 2026 constant-currency revenue growth guidance to a range of 7.0%-8.0% (up from 6.0%-7.0% previously) and adjusted diluted EPS guidance to $4.20-$4.30 (up from $4.15-$4.25). The Cardiopulmonary segment was a key driver, with 14.0% constant-currency growth, and Neuromodulation also saw solid growth of 7.6% on a constant-currency basis.
2. U.S. FDA Approval of the aura6000 System for Obstructive Sleep Apnea (OSA).
On March 19, 2026, LivaNova received U.S. Food and Drug Administration (FDA) premarket approval for its aura6000 System, a significant milestone for treating moderate to severe obstructive sleep apnea. This device is notable as the first and only hypoglossal nerve stimulation (HGNS) therapy approved by the FDA without a contraindication or warning related to complete concentric collapse. The approval was supported by robust 12-month data from the OSPREY randomized controlled trial, which demonstrated clinically significant responses and sustained improvements for patients. This regulatory clearance is expected to open a new growth market for LivaNova, with plans for a next-generation MRI-compatible device launch in the first half of 2027.
Show more
Stock Movement Drivers
Fundamental Drivers
The 12.4% change in LIVN stock from 1/31/2026 to 5/23/2026 was primarily driven by a 6.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5232026 | Change |
|---|---|---|---|
| Stock Price ($) | 65.71 | 73.83 | 12.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,349 | 1,433 | 6.3% |
| P/S Multiple | 2.7 | 2.8 | 5.8% |
| Shares Outstanding (Mil) | 55 | 55 | -0.1% |
| Cumulative Contribution | 12.4% |
Market Drivers
1/31/2026 to 5/23/2026| Return | Correlation | |
|---|---|---|
| LIVN | 12.4% | |
| Market (SPY) | 8.1% | 44.2% |
| Sector (XLV) | -2.7% | 33.9% |
Fundamental Drivers
The 40.3% change in LIVN stock from 10/31/2025 to 5/23/2026 was primarily driven by a 28.4% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5232026 | Change |
|---|---|---|---|
| Stock Price ($) | 52.63 | 73.83 | 40.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,309 | 1,433 | 9.5% |
| P/S Multiple | 2.2 | 2.8 | 28.4% |
| Shares Outstanding (Mil) | 55 | 55 | -0.2% |
| Cumulative Contribution | 40.3% |
Market Drivers
10/31/2025 to 5/23/2026| Return | Correlation | |
|---|---|---|
| LIVN | 40.3% | |
| Market (SPY) | 9.9% | 41.6% |
| Sector (XLV) | 4.8% | 36.3% |
Fundamental Drivers
The 99.5% change in LIVN stock from 4/30/2025 to 5/23/2026 was primarily driven by a 48.2% change in the company's Net Income Margin (%).| (LTM values as of) | 4302025 | 5232026 | Change |
|---|---|---|---|
| Stock Price ($) | 37.00 | 73.83 | 99.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,253 | 1,433 | 14.4% |
| Net Income Margin (%) | 5.0% | 7.5% | 48.2% |
| P/E Multiple | 31.8 | 37.7 | 18.4% |
| Shares Outstanding (Mil) | 54 | 55 | -0.6% |
| Cumulative Contribution | 99.5% |
Market Drivers
4/30/2025 to 5/23/2026| Return | Correlation | |
|---|---|---|
| LIVN | 99.5% | |
| Market (SPY) | 36.0% | 38.0% |
| Sector (XLV) | 8.6% | 33.3% |
Fundamental Drivers
The 54.1% change in LIVN stock from 4/30/2023 to 5/23/2026 was primarily driven by a 40.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5232026 | Change |
|---|---|---|---|
| Stock Price ($) | 47.90 | 73.83 | 54.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,022 | 1,433 | 40.3% |
| P/S Multiple | 2.5 | 2.8 | 12.4% |
| Shares Outstanding (Mil) | 53 | 55 | -2.2% |
| Cumulative Contribution | 54.1% |
Market Drivers
4/30/2023 to 5/23/2026| Return | Correlation | |
|---|---|---|
| LIVN | 54.1% | |
| Market (SPY) | 86.3% | 35.5% |
| Sector (XLV) | 18.0% | 31.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LIVN Return | 32% | -36% | -7% | -10% | 33% | 20% | 11% |
| Peers Return | 21% | -13% | 4% | 10% | 2% | -28% | -13% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| LIVN Win Rate | 50% | 42% | 42% | 50% | 50% | 60% | |
| Peers Win Rate | 55% | 47% | 52% | 63% | 52% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| LIVN Max Drawdown | -17% | -50% | -30% | -32% | -33% | -19% | |
| Peers Max Drawdown | -22% | -36% | -30% | -25% | -24% | -36% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, ABT, EW, INSP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/22/2026 (YTD)
How Low Can It Go
| Event | LIVN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -28.8% | -18.8% |
| % Gain to Breakeven | 40.4% | 23.1% |
| Time to Breakeven | 63 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -13.2% | -7.8% |
| % Gain to Breakeven | 15.2% | 8.5% |
| Time to Breakeven | 17 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -18.9% | -9.5% |
| % Gain to Breakeven | 23.3% | 10.5% |
| Time to Breakeven | 78 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.6% | -6.7% |
| % Gain to Breakeven | 34.4% | 7.1% |
| Time to Breakeven | 135 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -51.1% | -33.7% |
| % Gain to Breakeven | 104.5% | 50.9% |
| Time to Breakeven | 322 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -32.2% | -3.7% |
| % Gain to Breakeven | 47.4% | 3.9% |
| Time to Breakeven | 211 days | 6 days |
In The Past
LivaNova's stock fell -28.8% during the 2025 US Tariff Shock. Such a loss loss requires a 40.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | LIVN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -28.8% | -18.8% |
| % Gain to Breakeven | 40.4% | 23.1% |
| Time to Breakeven | 63 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.6% | -6.7% |
| % Gain to Breakeven | 34.4% | 7.1% |
| Time to Breakeven | 135 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -51.1% | -33.7% |
| % Gain to Breakeven | 104.5% | 50.9% |
| Time to Breakeven | 322 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -32.2% | -3.7% |
| % Gain to Breakeven | 47.4% | 3.9% |
| Time to Breakeven | 211 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -26.0% | -12.2% |
| % Gain to Breakeven | 35.1% | 13.9% |
| Time to Breakeven | 610 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -26.0% | -6.8% |
| % Gain to Breakeven | 35.1% | 7.3% |
| Time to Breakeven | 610 days | 15 days |
In The Past
LivaNova's stock fell -28.8% during the 2025 US Tariff Shock. Such a loss loss requires a 40.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About LivaNova (LIVN)
AI Analysis | Feedback
Here are 1-2 brief analogies to describe LivaNova (LIVN):- Like Medtronic, but specializing in implantable vagus nerve stimulation for neurological and mental health conditions.
- Similar to Getinge, but focused on critical heart-lung machines and temporary life support systems.
AI Analysis | Feedback
- Cardiopulmonary Products: Includes oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and connect for cardiopulmonary support.
- VNS Therapy System: An implantable device delivering vagus nerve stimulation (VNS) therapy for drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea.
- Advanced Circulatory Support Products: These temporary life support products provide cardiopulmonary and respiratory support solutions.
AI Analysis | Feedback
LivaNova (LIVN) primarily sells its therapeutic solutions to healthcare institutions and medical professionals. The company does not appear to have major customer companies that are publicly traded in the sense of supplying components or products for their own resale or integration into their own consumer offerings.
Based on the company description, the major categories of customers LivaNova serves are:
- Hospitals and Medical Institutions: These include hospitals, clinics, and other medical facilities where LivaNova's cardiopulmonary, neuromodulation, and advanced circulatory support products are utilized for patient care.
- Healthcare Providers and Medical Professionals: This category encompasses the individual professionals who directly use or decide on the use of LivaNova's products. Specifically mentioned are perfusionists, neurologists, neurosurgeons, and other physicians.
AI Analysis | Feedback
nullAI Analysis | Feedback
Vladimir Makatsaria, Chief Executive Officer
Vladimir Makatsaria was appointed Chief Executive Officer of LivaNova on March 1, 2024. He previously spent 27 years at Johnson & Johnson (J&J) in various global executive leadership roles. His most recent position at J&J MedTech was Company Group Chairman, where he led Ethicon, a global surgical technologies business. His tenure at J&J also included leadership roles for J&J China, J&J MedTech APAC, and Ethicon EMEA. He served as Chairman of the Board of the Asia Pacific Medical Technology Association and as an Advisory Board Member to Singapore Management University. Mr. Makatsaria holds a bachelor's degree in physiology, an MBA, and a master's in healthcare administration, all from the University of Minnesota.
Alex Shvartsburg, Chief Financial Officer
Alex Shvartsburg is the Chief Financial Officer of LivaNova, responsible for finance, accounting, and investor relations. He previously served as interim Chief Financial Officer of LivaNova from November 2020 to July 2021. Before his appointment as CFO, he led LivaNova's Corporate Financial Planning and Analysis group and was the International Region CFO. Prior to joining LivaNova in 2017, Mr. Shvartsburg was the CFO and Chief Operating Officer of Caligor, a private equity-backed clinical services organization, where he managed finance, operations, human resources, and information technology. His earlier career included finance leadership roles such as CFO of the Genetic Sciences division at Thermo Fisher Scientific, Senior Finance Director M&A at Life Technologies, and over 20 years in various finance roles at Johnson & Johnson. Mr. Shvartsburg holds a Bachelor of Science degree in Accounting from Drexel University and an MBA from LaSalle University, and is a Certified Management Accountant.
Ahmet Tezel, Chief Innovation Officer
Ahmet Tezel joined LivaNova in May 2024 as Chief Innovation Officer, overseeing innovation for the company’s core businesses, obstructive sleep apnea (OSA), and depression programs. He is also responsible for Enterprise Quality. With a 20-year track record, Dr. Tezel has guided teams in developing market-leading technologies across various medical fields. Before LivaNova, he was Company Group Chairman at Johnson & Johnson MedTech, where he led Global R&D and Innovation teams.
Philip Kowalczyk, Chief Strategy and Corporate Development Officer
Philip Kowalczyk became LivaNova’s Chief Strategy and Corporate Development Officer in August 2024. He brings extensive experience in creating and executing strategies within the medtech industry. Prior to LivaNova, he spent 16 years at Johnson & Johnson (J&J) Medtech, serving on the global leadership teams for both the Vision and Ethicon subsidiaries. His roles at J&J included Vice President of Business Development-Vision and Head of Asia Pacific Strategy and Business Development in Singapore, where he managed regional inorganic initiatives and integrated global acquisitions. For Ethicon, he served as Head of Global Strategy, Insights & Pricing, and Business Development Director. Mr. Kowalczyk holds a bachelor's degree in politics from Princeton University and an MBA in finance and strategy from The University of Michigan's Stephen M. Ross School of Business.
Natalia Kozmina, Chief Human Resources Officer
Natalia Kozmina joined LivaNova in January 2025 as Chief Human Resources Officer (CHRO). She has over 25 years of leadership experience in the medtech and life sciences sectors, having worked in Fortune 100 and FTSE 100 companies. Before her role at LivaNova, Ms. Kozmina was Executive Vice President, CHRO and ESG Stewardship of Convatec Group PLC. She also held senior human resources leadership positions at Iron Mountain and Smiths Group PLC.
AI Analysis | Feedback
The key risks to LivaNova's business include intense competition within its concentrated product portfolio, the challenges of navigating a stringent and evolving regulatory landscape, and significant ongoing litigation resulting in substantial financial liabilities.
- Intense Competition and Product Portfolio Concentration: LivaNova derives a substantial portion of its revenue from its Vagus Nerve Stimulation (VNS) therapy and heart-lung machines, with these two lines accounting for approximately 68% of product sales in 2024. This concentration makes the company particularly vulnerable to intense competition from larger medical device companies such as Medtronic and Abbott, who possess broader product portfolios and greater purchasing leverage with hospital groups. Such competition can lead to pricing pressure, potential loss of market share, and necessitates continuous investment in research and development to maintain innovation and provide robust clinical evidence.
- Regulatory Hurdles and Increasing Compliance Costs: As a global medical device company, LivaNova operates under stringent and continuously evolving regulatory oversight in the U.S. and internationally. The company faces increasing compliance costs, particularly related to regulations like the European Medical Device Regulation (MDR) and other product-related requirements. These regulatory hurdles can lead to delays in product approvals, increased operational complexities, and impact LivaNova's ability to effectively market and distribute its therapeutic solutions.
- Significant Litigation and Financial Liabilities: LivaNova is exposed to substantial legal challenges, most notably the ongoing SNIA litigation concerning environmental liabilities associated with its former parent company. A ruling in the first half of 2025 indicated a financial liability of approximately $363 million. This significant legal burden can strain the company's cash flow and impact its overall financial performance and profitability.
AI Analysis | Feedback
null
AI Analysis | Feedback
LivaNova PLC operates in several key medical device markets, with its primary products and services addressing cardiopulmonary, neuromodulation, and advanced circulatory support needs. The addressable markets for these solutions are substantial globally and within key regions.Cardiopulmonary and Advanced Circulatory Support
LivaNova's Cardiopulmonary and Advanced Circulatory Support segments are involved in products such as heart-lung machines, oxygenators, and temporary life support systems like Extracorporeal Membrane Oxygenation (ECMO) devices.
- The global heart-lung machine market was valued at approximately USD 2.51 billion in 2025 and is estimated to reach USD 4.54 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.86%. Another estimate places the global heart-lung machine market at USD 2.3 billion in 2023, projected to reach USD 4.5 billion by 2033, growing at a CAGR of 6.7%. The U.S. market for heart-lung machines was valued at USD 878.36 million in 2024 and is projected to reach USD 934.84 million in 2025.
- The global extracorporeal life support (ECLS) devices market was estimated at USD 2.5 billion in 2024 and is projected to reach USD 5.1 billion by 2034, registering a CAGR of 7.5%. Similarly, the global extracorporeal membrane oxygenation (ECMO) market size was around USD 582.63 million in 2024 and is predicted to grow to approximately USD 904.81 million by 2034. North America held the largest share of the extracorporeal life support devices market in 2024. The USA veno-venous extracorporeal life support (VV ECLS) devices market alone is estimated at USD 532.7 million in 2025 and is anticipated to reach USD 1.0 billion by 2035.
- More broadly, the global cardiopulmonary products market size was estimated to be USD 472.50 million in 2023 and is expected to reach USD 884.92 million by 2033.
Neuromodulation - VNS Therapy System
LivaNova's Neuromodulation segment primarily focuses on its VNS Therapy System for treating drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea.
- The global vagus nerve stimulation (VNS) market size is valued at USD 575.81 million in 2025 and is estimated to reach USD 974.30 million by 2034, growing at a CAGR of 6.06%. North America holds the largest share of the global VNS market. The U.S. VNS market was valued at USD 296.38 million in 2025.
- For drug-resistant epilepsy, a key application for VNS therapy, the VNS segment held around 22% of the global refractory epilepsy market in 2024, representing an estimated market size of approximately USD 1.47 billion. The broader global drug-resistant epilepsy treatment market was valued at USD 4,634.9 million in 2024 and is projected to reach USD 9,472.6 million by 2035. The top 7 major markets (US, EU4, UK, and Japan) for drug-resistant epilepsy were valued at USD 3.8 billion in 2024 and are expected to reach USD 6.4 billion by 2035.
- For difficult-to-treat depression, also known as treatment-resistant depression (TRD), the global TRD treatment market is projected to reach a valuation of USD 2.69 billion in 2025, with expectations to surge to USD 5.0 billion by 2035. Another source states the global treatment-resistant depression market is expected to grow from USD 2.16 billion in 2025 to USD 3.36 billion by 2031. North America leads this market.
- For obstructive sleep apnea, while specific market size for VNS therapy for OSA was not readily available, the broader global sleep apnea devices market was estimated at USD 7.11 billion in 2025 and is predicted to increase to USD 13.18 billion by 2034. North America dominates the sleep apnea devices market.
VITARIA System for Heart Failure
LivaNova is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. Information on the addressable market size for VNS specifically for heart failure is not currently available in the provided search results.
AI Analysis | Feedback
LivaNova (LIVN) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market expansions:
- Entry and Scaling in the Obstructive Sleep Apnea (OSA) Market: LivaNova is strategically entering the obstructive sleep apnea (OSA) market with its proximal hypoglossal nerve stimulation (p-HGNS) technology, specifically the aura6000 System. A Premarket Approval (PMA) submission to the FDA for this technology was targeted for the first half of 2025, with an independent commercial launch anticipated in the second half of 2027. This initiative is projected to generate significant revenue, with forecasts ranging from $200 million to $400 million by 2030.
- Continued Growth in the Core Cardiopulmonary Business: The Cardiopulmonary segment remains a strong foundation for LivaNova's growth. This includes sustained demand for consumables and the continued success and expansion of the Essenz Perfusion System. The Essenz system is a significant driver, with its launch in new markets such as China contributing to revenue growth. The company anticipates Cardiopulmonary revenue to grow between 7% and 8% in 2026.
- Expansion and Reimbursement Improvements in Neuromodulation for Epilepsy: The Neuromodulation segment, particularly VNS Therapy for drug-resistant epilepsy, is expected to continue its growth trajectory. Key drivers include increased provider reimbursement from the U.S. Centers for Medicare & Medicaid Services (CMS) for VNS Therapy procedures, effective January 1, 2026, which saw hospital outpatient payments rise approximately 48% for new patient implants and 47% for end-of-service procedures compared to 2025 rates. Additionally, new product launches like a connected care platform in 2026 and a Bluetooth-enabled implantable pulse generator in 2027 are expected to contribute to growth.
- Leveraging Innovation and New Product Introductions: Beyond specific market entries, LivaNova is focused on continuous innovation across its portfolio. This includes developing a new generation of oxygenators for the cardiopulmonary segment (planned for 2028) and enhancing its neuromodulation capabilities with new technologies like the cloud-based digital health platform which received FDA approval.
AI Analysis | Feedback
Share Repurchases
- LivaNova had a 3-year average share buyback ratio of -0.7, indicating net share issuance rather than repurchases over the period.
Share Issuance
- In March 2024, LivaNova priced a private offering of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029, with expected net proceeds of approximately $289.3 million. These notes are convertible into ordinary shares under certain conditions.
- The number of ordinary shares outstanding was approximately 53.9 million as of February 23, 2024, and is expected to be approximately 56 million for the full-year 2026.
Outbound Investments
- On June 1, 2021, LivaNova divested its Heart Valve business.
Capital Expenditures
- Capital expenditures were $25 million in 2021, $27 million in 2022, $35 million in 2023, and $47 million in 2024.
- For 2025, capital expenditures were approximately $71 million.
- LivaNova is investing in its core businesses and a transformational pipeline, including scaling Obstructive Sleep Apnea (OSA) and developing a next-generation oxygenator (estimated launch 2028), a connected care platform (estimated launch 2026), and a Bluetooth-enabled implantable pulse generator (estimated launch 2027).
Latest Trefis Analyses
Trade Ideas
Select ideas related to LIVN.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 76.22 |
| Mkt Cap | 67.7 |
| Rev LTM | 13,459 |
| Op Inc LTM | 2,924 |
| FCF LTM | 2,194 |
| FCF 3Y Avg | 1,590 |
| CFO LTM | 2,850 |
| CFO 3Y Avg | 2,232 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.7% |
| Rev Chg 3Y Avg | 11.2% |
| Rev Chg Q | 10.2% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 12.4% |
| Op Inc Chg 3Y Avg | 14.8% |
| Op Mgn LTM | 17.9% |
| Op Mgn 3Y Avg | 17.5% |
| QoQ Delta Op Mgn LTM | -0.3% |
| CFO/Rev LTM | 20.7% |
| CFO/Rev 3Y Avg | 17.9% |
| FCF/Rev LTM | 15.6% |
| FCF/Rev 3Y Avg | 12.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 67.7 |
| P/S | 3.1 |
| P/Op Inc | 20.9 |
| P/EBIT | 20.9 |
| P/E | 24.2 |
| P/CFO | 16.3 |
| Total Yield | 5.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.0% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.8% |
| 3M Rtn | -19.9% |
| 6M Rtn | -26.1% |
| 12M Rtn | -15.8% |
| 3Y Rtn | 0.7% |
| 1M Excs Rtn | -11.0% |
| 3M Excs Rtn | -30.3% |
| 6M Excs Rtn | -37.7% |
| 12M Excs Rtn | -46.3% |
| 3Y Excs Rtn | -81.9% |
Price Behavior
| Market Price | $73.83 | |
| Market Cap ($ Bil) | 4.0 | |
| First Trading Date | 10/19/2015 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $65.22 | $60.58 |
| DMA Trend | up | indeterminate |
| Distance from DMA | 13.2% | 21.9% |
| 3M | 1YR | |
| Volatility | 46.6% | 38.1% |
| Downside Capture | 105.18 | 94.34 |
| Upside Capture | 101.81 | 131.96 |
| Correlation (SPY) | 42.5% | 43.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.58 | 1.12 | 1.10 | 1.15 | 1.28 | 0.91 |
| Up Beta | 1.51 | 1.49 | 1.19 | 1.38 | 1.43 | 0.77 |
| Down Beta | 0.76 | 0.85 | 1.39 | 0.77 | 1.14 | 0.87 |
| Up Capture | 59% | 53% | 88% | 143% | 161% | 87% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 10 | 18 | 31 | 60 | 123 | 371 |
| Down Capture | 369% | 146% | 106% | 102% | 106% | 102% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 12 | 25 | 33 | 64 | 127 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LIVN | |
|---|---|---|---|---|
| LIVN | 71.3% | 38.1% | 1.49 | - |
| Sector ETF (XLV) | 16.0% | 14.5% | 0.80 | 34.2% |
| Equity (SPY) | 29.5% | 12.0% | 1.86 | 43.0% |
| Gold (GLD) | 35.5% | 26.8% | 1.11 | 10.7% |
| Commodities (DBC) | 42.9% | 18.7% | 1.77 | -22.2% |
| Real Estate (VNQ) | 15.2% | 13.1% | 0.82 | 32.8% |
| Bitcoin (BTCUSD) | -31.3% | 41.8% | -0.78 | 11.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LIVN | |
|---|---|---|---|---|
| LIVN | -1.7% | 39.6% | 0.06 | - |
| Sector ETF (XLV) | 5.7% | 14.7% | 0.21 | 35.9% |
| Equity (SPY) | 14.0% | 17.0% | 0.64 | 40.7% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 5.9% |
| Commodities (DBC) | 10.4% | 19.4% | 0.42 | 0.5% |
| Real Estate (VNQ) | 3.8% | 18.8% | 0.10 | 37.8% |
| Bitcoin (BTCUSD) | 11.6% | 55.3% | 0.41 | 18.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LIVN | |
|---|---|---|---|---|
| LIVN | 4.4% | 40.4% | 0.24 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 41.7% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 45.9% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 2.9% |
| Commodities (DBC) | 7.8% | 17.9% | 0.35 | 12.6% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 43.2% |
| Bitcoin (BTCUSD) | 66.7% | 66.9% | 1.06 | 12.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 15.1% | 24.6% | |
| 2/25/2026 | 1.8% | -0.9% | -8.3% |
| 11/5/2025 | -5.8% | -2.3% | 17.5% |
| 8/6/2025 | 11.1% | 18.8% | 36.5% |
| 5/7/2025 | 23.7% | 25.3% | 27.6% |
| 2/25/2025 | -15.8% | -15.7% | -19.4% |
| 10/30/2024 | -3.1% | -6.2% | -0.9% |
| 7/31/2024 | -3.7% | -10.7% | -5.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 15 | 11 | 11 |
| # Negative | 8 | 12 | 11 |
| Median Positive | 5.6% | 9.3% | 8.9% |
| Median Negative | -4.8% | -5.5% | -8.3% |
| Max Positive | 23.7% | 25.3% | 36.5% |
| Max Negative | -15.8% | -19.5% | -20.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/25/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 07/26/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue Growth | 7.0% | 7.5% | 8.0% | 15.4% | 1.0% | Raised | Guidance: 6.5% for 2026 |
| 2026 Adjusted Diluted EPS | 4.2 | 4.25 | 4.3 | 1.2% | Raised | Guidance: 4.2 for 2026 | |
| 2026 Adjusted Free Cash Flow | 160.00 Mil | 170.00 Mil | 180.00 Mil | 0 | Affirmed | Guidance: 170.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/25/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue Growth | 6.0% | 6.5% | 7.0% | ||||
| 2026 Adjusted Diluted EPS | 4.15 | 4.2 | 4.25 | ||||
| 2026 Adjusted Free Cash Flow | 160.00 Mil | 170.00 Mil | 180.00 Mil | ||||
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.